CALGARY, ALBERTA--(Marketwire - Oct. 3, 2008) - Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) ("SCT") announces today that it has elected to pay the final installment of the intellectual property acquisition of Stem Cell Therapeutics Inc. to Transition Therapeutics Inc. (TSX:TTH) (NASDAQ:TTHI) ("Transition") in common shares. The final payment of $1,650,000 was paid by SCT to Transition by issuing 23,272,633 shares, based on a 10-day average trading price of approximately C$0.07.
